Brief: MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
20/11/2023 13:12
Nov 20 (Reuters) - Mira Pharmaceuticals Inc MIRA.O :
* MIRA PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICENSING
AGREEMENT FOR
ORAL KETAMINE ANALOG, KETAMIR-2
* MIRA PHARMACEUTICALS INC - WILL HAVE EXCLUSIVE RIGHT IN
U.S.,
CANADA, AND MEXICO TO DEVELOP AND COMMERCIALIZE KETAMIR-2
* MIRA PHARMACEUTICALS INC - COLLABORATION INCLUDES A A $3
MILLION
LINE OF CREDIT EXTENDED BY MIRALOGX TO FUND INITIAL DEVELOPMENT
OF KETAMIR-2
* MIRA PHARMACEUTICALS INC - PARTNERSHIP WITH MIRALOGX, LLC
Source text for Eikon: ID:nPn5v5QBNa
Further company coverage: MIRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing